Member Info for flyingmachine

I Expect someone is just trying to their best to FUD but is failing miserably. Perhaps if they had been following Avacta over the past 3 years they would now be better informed but obviously he knows very little.

....and by the way I Expect that a few people noted that it should be 'their' not 'there'. I Expect someone needs more English lessons.

I think the case referenced in this thread is different to the case where ABDX is an 'interested party'. The most recent judgements from the ABDX related case is here.....

https://www.11kbw.com/content/uploads/Judgment-on-expert-evidence-30-Sep-21-FINAL-and-APPROVED.pdf

and I believe I have heard that another review of that case is due in May??

Commercialisation of the Gendrive AIHL test has begun, starting with the NHS, then Europe and onwards to ROW and USA. Just a reminder of the potential, remember there are cost savings for the health services that use the Genedrive AIHL test (avoids very expensive cochlear implants) plus the huge bonus that babies ending up in ICU can be prottected from unnecessary hearing loss by using this test.....

Market Opportunity :
• Approx 90,000 babies admitted each year to NICU in the UK
•
Assume ‘Western World” market opportunity 1.25M tests / year
• Test economics --<£10 to make, £35 to distributors, £50 --£85 direct depending on
reimbursement / country
• Approx 1:500 carry the mutation (Preliminary UK Biobank study of 500,000
individuals)
• Based on this mutation frequency approx. 2500 3000 babies could be prevented
from going deaf every year in EU/USA
• Global market value estimated at £40 --£65M per year depending on route to market

EarlofAim, your comments illustrate how little you know about Gendrive's AIHL test. You are ignorant - no babies are born with hearing loss!

I am expecting a raft of news on AIHL fairly soon, before the end of this month....

It was announced in November he was leaving to become CFO of musicMagpie, so he is probably clearing his slate. I don't read anything into it more than that. He'e already transferred 50000 shares to his wife, so that takes care of his remaining shares.

90,000/year, that's just for UK. I believe GDR have an initial commercial model that has a target of 1.25 million AIHL tests per year 'in the Western world', so UK/EU, USA. £65m per year.

McDunn, "The time has passed for covid stocks"......luckily GDR is not a Covid stock, though any sales of its POC test will be a nice bonus. The core strength of GDR will be its AIHL test, which will be coming onstream and selling both in the UK and EU in the very near future.....look out for news on AIHL test coming our way soon.

AIHL test is a 'no brainer' for hospital neonatal ICUs - it will save health service costs as well as saving babies from profound deafness - everyone wins. The test will sell itself. £35m revenue just for UK+EU, in relatively short order. ROW and USA will follow.

https://www.spectator.co.uk/article/has-the-good-law-project-been-dealt-a-blow-

Maybe has an impact to the GLP vs Health secretary case where Abingdon is an interested party? Does anyone have any idea when this case is being concluded. I believe there have been hearings in July, September and October last year but can't find anything more since then?

...in fact, there is already a pilot site in the EU using the AIHL test as a pre-cursor to wider EU distribution and sales.

Bighammer, you are correct. AIHL will start rolling out to the EU this year.

....meant to say holding ABDX..

'dead duck'......'hallmarks of another ODX'....if that's your view pumpky, why do you continue holding GDR? Or are you telling us porkies for your own agenda?

I personally would like to ask Avacta if the roadshow presentation will be added to the Investor information (presentations) section of their website, like other previous presentations. Does anyone have an appropriate (who deals with Avacta media relations) contact email address for FTI?

Agent, the CDC withdrew their own PCR test from EUA, as there were adequate alternative PCR tests in the market. It did not mean that CDC were withdrawing EUA from all PCR tests in the market.

AIHL.....no doubt there have been a few hoops to jump through in terms of approvals and sign offs within the NHS Trust around the clinical implementation requirements. These have not been within the control of Genedrive, hence no news as yet but must be close now.

Remember that the AIHL test is included in the PHE National Framework Agreement for Diagnostics Goods and Services,announced in 19 April RNS.....

"All of genedrive's currently available and CE marked products fall within the framework agreement: Genedrive® 96 SARS-CoV-2 Kit, Genedrive® HCV ID Kit, Genedrive® MT-RNR1 ID Kit"

Should make purchasing of the AIHL test easy to purchase by NHS trusts after (imminent) launch.

My own understanding is that the AIHL has been a roaring success, even to the extent that Mr McDermott will be spending his next 3 years on researching how best to further apply and take advantage of pharmacogenemics within the NHS....and Genedrive will be in the front seat alongside him, supporting with his research no doubt.

The PALOH study final report, apart from being presented next Tuesday at the Conference, is being published in a peer journal, it has already been submitted for full publication.

GM, about 1 in 7 babies end up in neonatal care. They don't need to 'get' sick, they are already sick.

Once the supporting data on the benefits of the Genedrive AIHL test spreads I do not think it will take too long for neonatal care guidelines in the UK and EU to mandate the use of the test. Why? Because....
- cost savings to the health services: each cochlear implant costs the NHS about £50k, plus the lifetime cost of supporting a deaf individual. That could save up to 200 cochlear implants in babies in just the UK (out of about 90,000 babies in the UK that end up in neonatal care). The cost of the test itself is expected to be around £35.
- saving the hearing in approximately 200 babies per year

That's just the UK.

The EU and USA markets are both 5 times bigger than the UK (so about 500,000 babies in neonatal care in each area every year). The additional benefit in the USA will be the avoidance of litigation brought by parents whose babies have suffered hearing loss due to not applying this test, when it becomes available in the USA.

We haven't considered RoW.